Loading…

Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis

The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2021-03, Vol.11 (3), p.187
Main Authors: Orlandi, Armando, Pontolillo, Letizia, Mele, Caterina, Pasqualoni, Mariangela, Pannunzio, Sergio, Cannizzaro, Maria Chiara, Cutigni, Claudia, Palazzo, Antonella, Garufi, Giovanna, Vellone, Maria, Ardito, Francesco, Franceschini, Gianluca, Sanchez, Alejandro Martin, Cassano, Alessandra, Giuliante, Felice, Bria, Emilio, Tortora, Giampaolo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93
cites cdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93
container_end_page
container_issue 3
container_start_page 187
container_title Journal of personalized medicine
container_volume 11
creator Orlandi, Armando
Pontolillo, Letizia
Mele, Caterina
Pasqualoni, Mariangela
Pannunzio, Sergio
Cannizzaro, Maria Chiara
Cutigni, Claudia
Palazzo, Antonella
Garufi, Giovanna
Vellone, Maria
Ardito, Francesco
Franceschini, Gianluca
Sanchez, Alejandro Martin
Cassano, Alessandra
Giuliante, Felice
Bria, Emilio
Tortora, Giampaolo
description The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months 16 months; HR 0.083, < 0.0001) and DFI (16 months 5 months; HR 0.17, = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.
doi_str_mv 10.3390/jpm11030187
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7998479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2504590294</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</originalsourceid><addsrcrecordid>eNpdkc1rGzEQxUVoqIOTU-9B0EuhOBl97GrVQ8E1bRNwSGmSs9DKWkdmd-VIWoP_-ypxYtwIgYbRj8ebeQh9InDBmITL1bojBBiQShyhEwqimHBOyw8H9QidxbiCfKqC0hI-ohFjFQAp4QQt525jA76xScd8rUm-2-LG71vJGfwj2Fzime5NZv_knu1T_Ian-M71y9bi6z4ml4bkfI__2hR8XGelrIynvW630cVTdNzoNtqz13eMHn79vJ9dTea3v69n0_nEcJBpInVdGFvWcmFK4A2IRoIGycFQXbHSksZWgpOmZMBqKPOItQDKgS40NAsj2Rh93-muh7qzC5ONBt2qdXCdDlvltVP___TuUS39RgkpKy6eBb68CgT_NNiYVOeisW2re-uHqGiR1yiIICyjn9-hKz-EPPALxQsJVPJMfd1RJq8lBtvszRBQzxmqgwwzfX7of8--Jcb-Aap5mEw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504590294</pqid></control><display><type>article</type><title>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Orlandi, Armando ; Pontolillo, Letizia ; Mele, Caterina ; Pasqualoni, Mariangela ; Pannunzio, Sergio ; Cannizzaro, Maria Chiara ; Cutigni, Claudia ; Palazzo, Antonella ; Garufi, Giovanna ; Vellone, Maria ; Ardito, Francesco ; Franceschini, Gianluca ; Sanchez, Alejandro Martin ; Cassano, Alessandra ; Giuliante, Felice ; Bria, Emilio ; Tortora, Giampaolo</creator><creatorcontrib>Orlandi, Armando ; Pontolillo, Letizia ; Mele, Caterina ; Pasqualoni, Mariangela ; Pannunzio, Sergio ; Cannizzaro, Maria Chiara ; Cutigni, Claudia ; Palazzo, Antonella ; Garufi, Giovanna ; Vellone, Maria ; Ardito, Francesco ; Franceschini, Gianluca ; Sanchez, Alejandro Martin ; Cassano, Alessandra ; Giuliante, Felice ; Bria, Emilio ; Tortora, Giampaolo</creatorcontrib><description>The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months 16 months; HR 0.083, &lt; 0.0001) and DFI (16 months 5 months; HR 0.17, = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm11030187</identifier><identifier>PMID: 33800160</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Abscesses ; Age ; Breast cancer ; Cancer therapies ; Liver ; Metastases ; Metastasis ; Mortality ; Patients ; Precision medicine ; Software ; Surgery</subject><ispartof>Journal of personalized medicine, 2021-03, Vol.11 (3), p.187</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</citedby><cites>FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</cites><orcidid>0000-0002-2950-3395 ; 0000-0001-5253-4678 ; 0000-0002-2003-9434 ; 0000-0003-1596-2862</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2504590294/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2504590294?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33800160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orlandi, Armando</creatorcontrib><creatorcontrib>Pontolillo, Letizia</creatorcontrib><creatorcontrib>Mele, Caterina</creatorcontrib><creatorcontrib>Pasqualoni, Mariangela</creatorcontrib><creatorcontrib>Pannunzio, Sergio</creatorcontrib><creatorcontrib>Cannizzaro, Maria Chiara</creatorcontrib><creatorcontrib>Cutigni, Claudia</creatorcontrib><creatorcontrib>Palazzo, Antonella</creatorcontrib><creatorcontrib>Garufi, Giovanna</creatorcontrib><creatorcontrib>Vellone, Maria</creatorcontrib><creatorcontrib>Ardito, Francesco</creatorcontrib><creatorcontrib>Franceschini, Gianluca</creatorcontrib><creatorcontrib>Sanchez, Alejandro Martin</creatorcontrib><creatorcontrib>Cassano, Alessandra</creatorcontrib><creatorcontrib>Giuliante, Felice</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><title>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months 16 months; HR 0.083, &lt; 0.0001) and DFI (16 months 5 months; HR 0.17, = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.</description><subject>Abscesses</subject><subject>Age</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Liver</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Software</subject><subject>Surgery</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkc1rGzEQxUVoqIOTU-9B0EuhOBl97GrVQ8E1bRNwSGmSs9DKWkdmd-VIWoP_-ypxYtwIgYbRj8ebeQh9InDBmITL1bojBBiQShyhEwqimHBOyw8H9QidxbiCfKqC0hI-ohFjFQAp4QQt525jA76xScd8rUm-2-LG71vJGfwj2Fzime5NZv_knu1T_Ian-M71y9bi6z4ml4bkfI__2hR8XGelrIynvW630cVTdNzoNtqz13eMHn79vJ9dTea3v69n0_nEcJBpInVdGFvWcmFK4A2IRoIGycFQXbHSksZWgpOmZMBqKPOItQDKgS40NAsj2Rh93-muh7qzC5ONBt2qdXCdDlvltVP___TuUS39RgkpKy6eBb68CgT_NNiYVOeisW2re-uHqGiR1yiIICyjn9-hKz-EPPALxQsJVPJMfd1RJq8lBtvszRBQzxmqgwwzfX7of8--Jcb-Aap5mEw</recordid><startdate>20210308</startdate><enddate>20210308</enddate><creator>Orlandi, Armando</creator><creator>Pontolillo, Letizia</creator><creator>Mele, Caterina</creator><creator>Pasqualoni, Mariangela</creator><creator>Pannunzio, Sergio</creator><creator>Cannizzaro, Maria Chiara</creator><creator>Cutigni, Claudia</creator><creator>Palazzo, Antonella</creator><creator>Garufi, Giovanna</creator><creator>Vellone, Maria</creator><creator>Ardito, Francesco</creator><creator>Franceschini, Gianluca</creator><creator>Sanchez, Alejandro Martin</creator><creator>Cassano, Alessandra</creator><creator>Giuliante, Felice</creator><creator>Bria, Emilio</creator><creator>Tortora, Giampaolo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2950-3395</orcidid><orcidid>https://orcid.org/0000-0001-5253-4678</orcidid><orcidid>https://orcid.org/0000-0002-2003-9434</orcidid><orcidid>https://orcid.org/0000-0003-1596-2862</orcidid></search><sort><creationdate>20210308</creationdate><title>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</title><author>Orlandi, Armando ; Pontolillo, Letizia ; Mele, Caterina ; Pasqualoni, Mariangela ; Pannunzio, Sergio ; Cannizzaro, Maria Chiara ; Cutigni, Claudia ; Palazzo, Antonella ; Garufi, Giovanna ; Vellone, Maria ; Ardito, Francesco ; Franceschini, Gianluca ; Sanchez, Alejandro Martin ; Cassano, Alessandra ; Giuliante, Felice ; Bria, Emilio ; Tortora, Giampaolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abscesses</topic><topic>Age</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Liver</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Software</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orlandi, Armando</creatorcontrib><creatorcontrib>Pontolillo, Letizia</creatorcontrib><creatorcontrib>Mele, Caterina</creatorcontrib><creatorcontrib>Pasqualoni, Mariangela</creatorcontrib><creatorcontrib>Pannunzio, Sergio</creatorcontrib><creatorcontrib>Cannizzaro, Maria Chiara</creatorcontrib><creatorcontrib>Cutigni, Claudia</creatorcontrib><creatorcontrib>Palazzo, Antonella</creatorcontrib><creatorcontrib>Garufi, Giovanna</creatorcontrib><creatorcontrib>Vellone, Maria</creatorcontrib><creatorcontrib>Ardito, Francesco</creatorcontrib><creatorcontrib>Franceschini, Gianluca</creatorcontrib><creatorcontrib>Sanchez, Alejandro Martin</creatorcontrib><creatorcontrib>Cassano, Alessandra</creatorcontrib><creatorcontrib>Giuliante, Felice</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orlandi, Armando</au><au>Pontolillo, Letizia</au><au>Mele, Caterina</au><au>Pasqualoni, Mariangela</au><au>Pannunzio, Sergio</au><au>Cannizzaro, Maria Chiara</au><au>Cutigni, Claudia</au><au>Palazzo, Antonella</au><au>Garufi, Giovanna</au><au>Vellone, Maria</au><au>Ardito, Francesco</au><au>Franceschini, Gianluca</au><au>Sanchez, Alejandro Martin</au><au>Cassano, Alessandra</au><au>Giuliante, Felice</au><au>Bria, Emilio</au><au>Tortora, Giampaolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2021-03-08</date><risdate>2021</risdate><volume>11</volume><issue>3</issue><spage>187</spage><pages>187-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months 16 months; HR 0.083, &lt; 0.0001) and DFI (16 months 5 months; HR 0.17, = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33800160</pmid><doi>10.3390/jpm11030187</doi><orcidid>https://orcid.org/0000-0002-2950-3395</orcidid><orcidid>https://orcid.org/0000-0001-5253-4678</orcidid><orcidid>https://orcid.org/0000-0002-2003-9434</orcidid><orcidid>https://orcid.org/0000-0003-1596-2862</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2075-4426
ispartof Journal of personalized medicine, 2021-03, Vol.11 (3), p.187
issn 2075-4426
2075-4426
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7998479
source Open Access: PubMed Central; Publicly Available Content Database
subjects Abscesses
Age
Breast cancer
Cancer therapies
Liver
Metastases
Metastasis
Mortality
Patients
Precision medicine
Software
Surgery
title Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20Metastasectomy%20for%20Metastatic%20Breast%20Cancer%20Patients:%20A%20Single%20Institution%20Retrospective%20Analysis&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Orlandi,%20Armando&rft.date=2021-03-08&rft.volume=11&rft.issue=3&rft.spage=187&rft.pages=187-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm11030187&rft_dat=%3Cproquest_pubme%3E2504590294%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2504590294&rft_id=info:pmid/33800160&rfr_iscdi=true